[1]
|
D. E. McFarlin and H. F. McFarland, “Multiple Sclerosis,” The New England Journal of Medicine, Vol. 307, 1982, pp. 1183-1188.
|
[2]
|
J. E. Friedman, M. J. Lyons, G. Cu, D. V. Ablashl, J. E. Whitman, M. Edgar, M. Koskiniemi, A. Vaheri and J. B. Zabriskie, “The Association of the Human Herpesvirus-6 and MS,” Multiple Sclerrosis, Vol. 5, No. 5, pp. 355-362.
|
[3]
|
H. Lassmann, “Comparative Neuropathology of Chronic Experimental Allergic Encephalomyelitis and Multiple Sclerosis,” Springer Verlag, Berlin, 1983.
|
[4]
|
J. F. Kurtzke, “Epidemiological Evidence for Multiple Sclerosis as an Infection,” Clinical Microbiology Review, Vol. 6, No. 4, 1993, pp. 382-427.
|
[5]
|
S. S. Solden, R. Berti, N. Salem, et al., “Association of Human Herpes Virus 6 (HHV-6) With Multiple Sclerosis: Increased Igm Response to HHV-6 Early Antigen and Detection of Plasma HHV-6 DNA,” Nature Medicine, Vol. 3, 1997, pp. 1394-1397.
|
[6]
|
S. F. Hunterand D. A. Hafler, “Ubiquitous Pathogens. Links between Infection and Autoimmunity in MS,” Neurology, Vol. 55, No. 2, 2000, pp. 164-165.
|
[7]
|
A. K. Abbas, K. M. Murphy and A. Sher, “Functional Diversity of Helper T Lymphocytes,” Nature, Vol. 383, No. 6603, 1996, pp. 787-793.
|
[8]
|
M. Allegretta, J. A. Nicklas and S. Sriram, R. J. Albertini and O. T. Abramsky, “Cells Responsive to Myelin Basic Protein in Patients with Multiple Sclerosis,” Science, Vol. 247, No. 4943, 1990, pp. 718-721.
|
[9]
|
K. Bandobashi, M. Daibata, M. Kamioka, Y. Tanaka, I. Kubonishi, H. Taguchi, Y. Ohtsuki and I. Miyoshi, “Human Herpesvirus 6 (HHV-6)-Positive Burkitt’s Lymphoma: Establishment of a Novel Cell Line Infected with HHV-6,” Blood, Vol. 90, No. 3, 1997, pp. 1200-1207.
|
[10]
|
W. L. McDonald, D. A. S. Compston, G. Edan, D. E. Goodkin, H. P. Hartung, F. D. Lublin, et al., “Diagnostic Criteria for MS: Guidelines from the International Panel on the Diagnosis of MS,” Annals of Neurology, Vol. 50, No. 1, 2001, pp. 121-127.
|
[11]
|
C. M. Poser, D. W. Paty, L. Scheinberg, W. I. McDonald, F. A. Davis, G. C. Ebers, et al., “New Diagnostic Criteria for Multiple Sclerosis: Guidelines for Research Protocols,” Ann Neurol, Vol. 13, No. 2, pp. 227-231.
|
[12]
|
S. Beer, K. M. R?sler and C. W. Hess, “Diagnostic Value of Paraclinical Tests In Multiple Sclerosis: Relative Sensitivities and Specificities for Reclassification According to the Poser Committee Criteria,” Journal of Neurology Neurosurgery Psychiatry, Vol. 59, No. 2, pp. 152-159.
|
[13]
|
M. L. Opsahl and P. G. Kennedy, “Investigating the Presence of Human Herpesvirus 7 And 8 in Multiple Sclerosis and Normal Control Brain Tissue,” Journal of the Neurological Sciences, Vol. 240, No. 1-2, pp. 37-44.
|
[14]
|
A. Simmons, “Herpesvirus and Multiple Sclerosis,” Herpes, Vol. 8, No. 3, pp. 60-63.
|
[15]
|
E. Norrby, H. Link and J. E. Olsson. “Comparison of Antibodies Against Different Viruses in Cerebrospinal Fluid and Plasma Samples from Patients with Multiple Sclerosis,” Infect Inmunology, Vol. 10, 1974, pp. 688.
|
[16]
|
R. T. Johnson, “The Virology of Demyelinating Diseases,” Annals Neurology, Vol. 36, 1994, pp. 54-60.
|
[17]
|
C. Martin, M. Enbom, M. S?derstr?m, S. Fredrikson, H. Dahl, J. Lycke, et al., “Absence of Seven Human Herpesviruses, Including HHV-6, By Polymerase Chain Reaction In CSF And Blood From Patients With Multiple Sclerosis And Optic Neuritis,” Acta Neurological Scandinavica, Vol. 95, No. 5, 1997, pp. 280-283.
|
[18]
|
M. Enbom, F. Z. Wang, S. Fredrikson, C. Martin, H. Dahl and A. Linde, “Similar Humoral and Cellular Immunological Reactivities to Human Herpesvirus 6 in Patients with Multiple Sclerosis and Controls,” Clinical Diagnostic Lab Immunology, Vol. 6, No. 4, 1999, pp. 545-549.
|
[19]
|
M. Enbom, “Multiple Sclerosis and Kaposi’s Sacoma- Chronic Diseases Associated with New Human Herpesviruses?” Scandinavial Journal Infectious Diseases, Vol. 33, No. 9, 2001, pp. 648-658.
|
[20]
|
K. K. Knox, D. Harrington and D. R. Carrigan, “Active Human Herpesvirus Type 6 Infections are Present in the Central Nervous System, Lymphoid Tissues and Peripheral Blood of Patients with Multiple Sclerosis,” Annals Neurology, Vol. 44, 1998, p. 485.
|
[21]
|
M. Mayne, J. Krishnan, L. Metz, et al., “Infrequent Detection of Human Herpesvirus 6 DNA in Peripheral Blood Mononuclear Cells from Multiple Sclerosis Patients,” Annals Neurology, Vol. 44, No. 3, 1998, pp. 391- 394.
|
[22]
|
E. Merelli, R. Bedin, P. Sola, P. Barozzi, G. L. Mancardi, G. Ficarra et al., “Human Herpes Virus 6 and Human Herpes Virus 8 DNA Sequences in Brains of Multiple Sclerosis Patients, Normal Adults and Children,” Journal Neurology, Vol. 244, No. 7, 1997, pp. 450-454.
|
[23]
|
K. Felgenhauer and H.Reiber, “The Diagnostic Significance of Antibody Specificity Indices in Multiple Sclerosis and Herpesvirus Induced Diseases of the Nervous System,” The Journal of Clinical Investigation, Vol. 70, No. 1, 1992, pp. 28-37.
|
[24]
|
A. Rotola, E. Cassai, M. R. Tola, E. Granieri and D. Di Luca, “Human Herpesvirus 6 is Latent in Peripheral Blood of Patients with Relapsing-Remitting Multiple Sclerosis,” Journal of Neurology Neurosurgery Psychiatry, Vol. 67, No. 4, pp. 529-531.
|
[25]
|
J. Lycke, B. Svennerholm, E. Hjelmquist, et al., “Acyclovir Treatment of Relapsing Remitting Multiple Sclerosis. Randomized Placebo-Controlled, Double-Blind Study,” Journal Neurology, Vol. 243, No. 3, pp. 214-224.
|
[26]
|
K. R. Beutner, “Valacyclovir: A Review of Its Antiviral Activity, Pharmacokinetic Properties, and Clinical Efficacy,” Antiviral Research, Vol. 28, No. 4, 1995, pp. 281- 290.
|